SEC Form 4 · accession 0001213900-26-076429
KAZIA THERAPEUTICS LTD · KZIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Bonacorda
Officer — VP, Finance and Controller
Period of report
Jan 8, 2026
Accepted (ET)
Jul 8, 2026 · 4:58 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001075880
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $6.78 | Jan 8, 2026 | A | 150,000 | A | — | — | ADSs | 150,000 | 150,000 | D |
Explanation of responses
- F1Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.